IB

Indo Borax & Chemicals Ltd

Q1 FY27Chemicals & Petrochemicals

Indo Borax & Chemicals Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹511
Market cap₹1.7K Cr
P/E33.8
Updated9 Sept 2026
Read4 min read

The short version

Indo Borax expects revenue of Rs. The company aims for long-term value creation rather than just quarter-to-quarter focus. - For FY 27-28, an EBITDA margin of around 20% is expected, slightly lower than the exceptional Q1 EBITDA of 28%. - Revenue guidance for the current year is Rs.

From Indo Borax & Chemicals Ltd's Q1 FY27 earnings-call transcript · updated 9 Sept 2026.

Revenue & Sales Performance

  • Indo Borax expects revenue of Rs. 250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms.
  • Plans to add capacities in Boron oxide and Boric acid to drive further margin expansion and year-on-year growth.
  • Kronox's revenue potential is expected to be 3 to 3.5 times current levels after completion of Dahej capex.
  • Dahej capex benefits to start reflecting from FY29, with full impact by FY30-31.
  • Kronox's existing plants are at full utilization but operational improvements could provide 15-20% additional capacity before capex benefits.

2 more points from Indo Borax & Chemicals Ltd's call on revenue

Every concall, every company

Profitability & Margins

See what Indo Borax & Chemicals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Indo Borax plans approximately Rs. 50 crores capex over the next 2-3 years, primarily in Boron Oxide (Rs. 20 crores) and Boric Acid (Rs. 20-25 crores), with some allowance for inflation rounding to Rs. 50 crores.
  • There is also planned capex for Zinc Borate as part of the overall Rs. 50 crores investment in specialty chemical expansion.
  • Kronox has a capex plan of about Rs. 110 crores to be executed in phases, with Rs. 80 crores already in cash on their balance sheet. The initial phase will use Rs. 55-60 crores, fully funded from internal accruals.
  • The Kronox capex execution is expected to take 18-24 months.

2 more points from Indo Borax & Chemicals Ltd's call on capex

Every concall, every company

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 2
2Solar Industries
Rev 2Mar 1
3
Rev 2Mar 1
4
Rev 2Mar 3
5
Rev 3Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Indo Borax & Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript from the provided pages does not explicitly mention details about the current or expected order book or pending orders for Indo Borax & Chemicals Limited or Kronox. However, related insights include: - Q1 FY27 showed robust execution with steady orders across domestic markets supporting revenue and profit growth (Page 4). - The company is focusing on capacity utilization improvement and higher realization amid steady orders (Page 4). - No specific numbers or values of order book or pending orders were disclosed during the call. Therefore, no precise figures or commentary on pending or expected orders are available in this transcript.

Indo Borax & Chemicals Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹63 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Indo Borax & Ch.'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Lords Chloro Alkali Ltd (Q1 FY27)

    106.34 crore, a 6.88% YoY increase from Rs. Key investor presentation takeaways from Lords Chloro Alkali Ltd's Q1 FY27 investor presentation — and how it ranks

  • Prasol Chemicals Ltd (Q1 FY27)

    Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank

  • Fine Organic Industries Ltd (Q1 FY27)

    Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

  • Chemfab Alka. (Q1 FY27)

    Consolidated Q1FY27 Revenue from Operations:** ₹73.16 crore, down 20.08% YoY (from ₹91.54 crore in Q1FY26). Key concall takeaways from Chemfab Alkalis Ltd's Q1…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Indo Borax & Chemicals Ltd and 1,500+ more calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Indo Borax & Chemicals Ltd Q1 FY27 results?

Indo Borax expects revenue of Rs. The company aims for long-term value creation rather than just quarter-to-quarter focus. - For FY 27-28, an EBITDA margin of around 20% is expected, slightly lower than the exceptional Q1 EBITDA of 28%. - Revenue guidance for the current year is Rs.

What is Indo Borax & Chemicals Ltd share price analysis?

Indo Borax & Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 33.8 with a market cap of ₹1,652 Cr. Investors should review the full earnings analysis for detailed insights.

Is Indo Borax & Chemicals Ltd planning capital expenditure?

Indo Borax plans approximately Rs.

Keep Indo Borax & Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.